Evidence map›Paper›PMID 31659562›Full record

ArticleEJNMMI radiopharmacy and chemistry2019

Clinical-grade N-(4-[

Elly L van der Veen, Inês F Antunes, Petra Maarsingh, Janet Hessels-Scheper, Rolf Zijlma, Hendrikus H Boersma, Annelies Jorritsma-Smit, Geke A P Hospers, Elisabeth G E de Vries, Marjolijn N Lub-de Hooge and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. [European journal of nuclear medicine and molecular imaging · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. The aluminium-[EJNMMI radiopharmacy and chemistry · 2021
    Review
  11. Role of Peptides in Diagnostics.International journal of molecular sciences · 2021
    Review
  12. Radiolabelling anReaction chemistry & engineering · 2021
    Article
  13. An Improved Synthesis of N-(4-[Molecules (Basel, Switzerland) · 2021
    Article
  14. Development and Evaluation of Interleukin-2-Derived Radiotracers for PET Imaging of T Cells in Mice.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020
    Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Elly L van der VeenDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
Inês F AntunesDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
Petra MaarsinghDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
Janet Hessels-ScheperDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
Rolf ZijlmaDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
Hendrikus H BoersmaDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
Annelies Jorritsma-SmitDepartment of Clinical Pharmacy and Pharmacology, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
Geke A P HospersDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
Elisabeth G E de VriesDepartment of Medical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
Marjolijn N Lub-de HoogeDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
Erik F J de VriesDepartment of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands. e.f.j.de.vries@umcg.nl.ORCID http://orcid.org/0000-0002-6915-1590
University Medical Center Groningen · NLHanze University of Applied Sciences · NL

Funding

Innovative Medicines Initiative No 116106 (TRISTAN)ZonMw 95104008
6 · The paper itself

Abstract

backgroundMolecular imaging of immune cells might be a potential tool for response prediction, treatment evaluation and patient selection in inflammatory diseases as well as oncology. Targeting interleukin-2 (IL2) receptors on activated T-cells using positron emission tomography (PET) with N-(4-[

methodsThe preclinical synthesis of [

resultsRestrictions in the [

conclusionsTo enable the use of [

Indexed as

Fluor-18ImmunotherapyInflammationInterleukin-2Molecular imagingPositron emission tomographyT-cells

Identifiers

PMID31659562
PMCPMC6637160
OpenAlexW2962406635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.